CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
2023 年 EBMT 造血细胞移植与细胞治疗报告：髓系恶性肿瘤异基因 HCT 使用增加，CAR-T 使用增加以自体 HCT 减少为代价
英文原题：The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT.
查看英文原题
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2023年，696个欧洲中心报告了43,902名患者中的47,731例HCT（20,485例（42.9%）异基因和27,246例（57.1%）自体）。6042名患者接受了先进细胞疗法，其中4888例为CAR-T。与前一年相比，CAR-T 增加（+52.5%），异基因HCT增加（+7.8%），但自体HCT没有增加（+0.4%）。异基因HCT的主要适应症为髓系恶性肿瘤（11,748例；60.7%）、淋系恶性肿瘤（4,850例；25.0%）和非恶性疾病（2558例；13.2%）。异基因HCT的使用在AML（+12.1%）和NHL（+11.0%）中增加，尤其是T-NHL（+25.6%）。自体HCT的主要适应症为淋巴瘤（7890例；32.2%）、PCD（14,271例；58.2%）和实体瘤（1608例；6.6%），自身免疫性疾病的数量正在恢复。在异基因HCT患者中，同胞供者的使用增加了+1.0%，单倍体相合供者增加了+11.7%，无关供者增加了+11.1%。脐血HCT再次下降-5.4%。儿童HCT活动略有增加（5455例；+0.1%），异基因（4111例；-0.5%）和自体HCT（1344例：+1.7%）之间存在差异。CAR-T 的使用增加至累计总数13,927名患者，包括因自身免疫性疾病接受治疗的患者。
总体而言，数据表明已从疫情低谷中完全恢复，细胞疗法增加而以自体HCT为代价。异基因HCT活动集中于髓系恶性肿瘤。
展开英文摘要原文
In 2023, 47,731 HCT (20,485 (42. 9%) allogeneic and 27,246 (57. 1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were CAR-T. Compared to the previous year there was an increase in CAR-T (+52. 5%), in allogeneic HCT (+7. 8%) but none in autologous HCT (+0. 4%). Main indications for allogeneic HCT were myeloid (11,748; 60. 7%), lymphoid malignancies (4,850; 25. 0%), and non-malignant disorders (2558; 13. 2%). Use of allogeneic HCT increased for AML (+12. 1%) and for NHL (+11. 0%), particularly in T-NHL (+25. 6%).
Main indications for autologous HCT were lymphomas (7890; 32. 2%), PCD (14,271; 58. 2%), and solid tumors (1608; 6. 6%) with recovering numbers for autoimmune diseases. In patients with allogeneic HCT, the use of sibling donors increased by +1. 0%, haploidentical donors by +11. 7%, and unrelated donors by +11.
1%. Cord blood HCT decreased again by -5. 4%. Pediatric HCT activity increased slightly (5455; +0. 1%) with differences between allogeneic (4111; -0. 5%) and autologous HCT (1344: +1. 7%). Use of CAR-T increased to a cumulative total of 13,927 patients including patients treated for autoimmune diseases.
Overall, numbers show a complete recovery from the pandemic dip with increased cellular therapy at the expense of autologous HCT. Allogeneic HCT activity focuses on myeloid malignancies.
论文信息
- 作者
- Passweg JR、Baldomero H、Atlija M、Kleovoulou I、Witaszek A、Alexander T、Angelucci E、Averbuch D
- 第一作者单位
- EBMT Activity Survey Office Basel, Hematology Division, University Hospital, Basel, Switzerland.Switzerland
- 通讯作者单位
- EBMT Activity Survey Office Basel, Hematology Division, University Hospital, Basel, Switzerland. helen.baldomero@usb.ch.Switzerland
- 期刊
- Bone marrow transplantation2025 Apr
- 原文标识
- PubMed 39939433 · DOI 10.1038/s41409-025-02524-2